Strategic partnerships Form a collaboration with Actarmo Medical to jointly offer inhalation development services from preclinical stages through formulation, device development, and clinical trial supplies, expanding reach into German and European clients seeking integrated inhalation solutions.

PreciseInhale leverage Position PreciseInhale as a differentiator for customers needing precise aerosol dosing and PK data to de-risk early inhaled drug development, targeting sponsors of generics, INDs, and biologics who require high-quality data for regulatory submissions.

Clinical predictability Highlight unprecedented clinical predictability and reduced reliance on animals to attract biotech and pharma companies prioritizing ethical, data-driven, and cost-efficient inhalation programs.

Thought leadership Leverage founder CSO Per Gerde’s authority in inhalation toxicology to engage academic and industry partners, offering joint webinars, white papers, and advisory services to win projects and enhance credibility.

Growth channels Target small-to-midcap biotech firms and contract manufacturers seeking specialized inhalation capabilities, offering modular services from early dosing optimization to full device and formulation development to accelerate timelines.